Response rates for O-ICE or O-DHAP
| . | O-DHAP (n = 26) . | O-ICE (n = 33) . | Total (n = 59) . |
|---|---|---|---|
| Response, n (%) | |||
| CR | 11 (42) | 11 (33) | 22 (37) |
| PR | 7 (27) | 7 (21) | 14 (24) |
| SD | 4 (15) | 9 (27) | 13 (22) |
| PD | 4 (15) | 6 (18) | 10 (17) |
| ORR, n (%) | 18 (69) | 18 (55) | 36 (61) |
| 95% CI | (48.2, 85.7) | (36.4, 71.9) | (47.4, 73.5) |
| CR, n (%) | 11 (42) | 11 (33) | 22 (37) |
| 95% CI | (23.4, 63.1) | (18.0, 51.8) | (25.0, 50.9) |
| Histology, n (%) | |||
| DLBCL + grade 3b FL | 21 | 27 | 48 |
| ORR | 14 (67) | 13 (48) | 27 (56) |
| 95% CI | (43.0, 85.4) | (28.7, 68.1) | (41.2, 70.5) |
| Transformed FL, n (%) | 5 | 6 | 11 |
| ORR | 4 (80) | 5 (83) | 9 (82) |
| 95% CI | (28.4, 99.5) | (35.9, 99.6) | (48.2, 97.7) |
| saaIPI, n (%) | |||
| saaIPI: 0-1 | 13 | 17 | 30 |
| ORR | 10 (77) | 9 (53) | 19 (63) |
| 95% CI | (46.2, 95.0) | (27.8, 77.0) | (43.9, 80.1) |
| CR | 7 (54) | 6 (35) | 13 (43) |
| 95% CI | (25.1, 80.8) | (14.2, 61.7) | (25.5, 62.6) |
| saaIPI: 2-3 | 13 | 16 | 29 |
| ORR | 8 (62) | 9 (56) | 17 (59) |
| 95% CI | (31.6, 86.1) | (29.9, 80.2) | (38.9, 76.5) |
| CR | 4 (31) | 5 (31) | 9 (31) |
| 95% CI | (9.1, 61.4) | (11.0, 58.7) | (15.3, 50.8) |
| First-line response, n (%) | |||
| CR >12 mo | 4 | 8 | 12 |
| CR | 3 (75) | 5 (63) | 8 (67) |
| PR | 1 (25) | 1 (13) | 2 (17) |
| SD | 0 | 0 | 0 |
| PD | 0 | 2 (25) | 2 (17) |
| ORR | 4 (100) | 6 (75) | 10 (83) |
| 95% CI | (39.8, 100) | (34.9, 96.8) | (51.6, 97.9) |
| CR ≤12 mo, PR, SD, PD, or unknown* | 22 | 25 | 47 |
| CR | 8 (36) | 6 (24) | 14 (30) |
| PR | 6 (27) | 6 (24) | 12 (26) |
| SD | 4 (18) | 9 (36) | 13 (28) |
| PD | 4 (18) | 4 (16) | 8 (17) |
| ORR | 14 (64) | 12 (48) | 26 (55) |
| 95% CI | (40.7, 82.8) | (27.8, 68.7) | (40.1, 69.8) |
| . | O-DHAP (n = 26) . | O-ICE (n = 33) . | Total (n = 59) . |
|---|---|---|---|
| Response, n (%) | |||
| CR | 11 (42) | 11 (33) | 22 (37) |
| PR | 7 (27) | 7 (21) | 14 (24) |
| SD | 4 (15) | 9 (27) | 13 (22) |
| PD | 4 (15) | 6 (18) | 10 (17) |
| ORR, n (%) | 18 (69) | 18 (55) | 36 (61) |
| 95% CI | (48.2, 85.7) | (36.4, 71.9) | (47.4, 73.5) |
| CR, n (%) | 11 (42) | 11 (33) | 22 (37) |
| 95% CI | (23.4, 63.1) | (18.0, 51.8) | (25.0, 50.9) |
| Histology, n (%) | |||
| DLBCL + grade 3b FL | 21 | 27 | 48 |
| ORR | 14 (67) | 13 (48) | 27 (56) |
| 95% CI | (43.0, 85.4) | (28.7, 68.1) | (41.2, 70.5) |
| Transformed FL, n (%) | 5 | 6 | 11 |
| ORR | 4 (80) | 5 (83) | 9 (82) |
| 95% CI | (28.4, 99.5) | (35.9, 99.6) | (48.2, 97.7) |
| saaIPI, n (%) | |||
| saaIPI: 0-1 | 13 | 17 | 30 |
| ORR | 10 (77) | 9 (53) | 19 (63) |
| 95% CI | (46.2, 95.0) | (27.8, 77.0) | (43.9, 80.1) |
| CR | 7 (54) | 6 (35) | 13 (43) |
| 95% CI | (25.1, 80.8) | (14.2, 61.7) | (25.5, 62.6) |
| saaIPI: 2-3 | 13 | 16 | 29 |
| ORR | 8 (62) | 9 (56) | 17 (59) |
| 95% CI | (31.6, 86.1) | (29.9, 80.2) | (38.9, 76.5) |
| CR | 4 (31) | 5 (31) | 9 (31) |
| 95% CI | (9.1, 61.4) | (11.0, 58.7) | (15.3, 50.8) |
| First-line response, n (%) | |||
| CR >12 mo | 4 | 8 | 12 |
| CR | 3 (75) | 5 (63) | 8 (67) |
| PR | 1 (25) | 1 (13) | 2 (17) |
| SD | 0 | 0 | 0 |
| PD | 0 | 2 (25) | 2 (17) |
| ORR | 4 (100) | 6 (75) | 10 (83) |
| 95% CI | (39.8, 100) | (34.9, 96.8) | (51.6, 97.9) |
| CR ≤12 mo, PR, SD, PD, or unknown* | 22 | 25 | 47 |
| CR | 8 (36) | 6 (24) | 14 (30) |
| PR | 6 (27) | 6 (24) | 12 (26) |
| SD | 4 (18) | 9 (36) | 13 (28) |
| PD | 4 (18) | 4 (16) | 8 (17) |
| ORR | 14 (64) | 12 (48) | 26 (55) |
| 95% CI | (40.7, 82.8) | (27.8, 68.7) | (40.1, 69.8) |
Includes 2 subjects with an unknown response but a PFS <12 months to first-line treatment. CI, confidence interval; PD, progressive disease; PR, partial response.